STOCK TITAN

ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Eikon Therapeutics ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares of common stock, representing 5.2% of the class. The filing cites a shares outstanding base of 53,984,337 after giving effect to the offering described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.

Platinum Falcon B 2018 RSC Limited is reported as the direct owner of 1,147,138 shares (shown as 2.1% of the class); Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority and certain voting/dispositive powers are shared between them.

Positive

  • None.

Negative

  • None.

Insights

ADIA disclosed a meaningful passive stake in Eikon, totaling 2,816,714 shares (5.2%).

The filing lists 1,669,576 shares held directly by Abu Dhabi Investment Authority and 1,147,138 shares held by Platinum Falcon B 2018 RSC Limited, with shared voting and dispositive powers noted.

The percent figures are tied to a base of 53,984,337 shares outstanding "after giving effect to the completion of the offering" described in the prospectus filed on February 5, 2026. Subsequent disclosures may clarify any changes in position.

Filing indicates related entities with shared control; attribution follows regulatory aggregation rules.

The excerpt explains that Platinum Falcon is a wholly owned subsidiary of ADIA and, under applicable rules, ADIA "may be deemed to be the beneficial owner" of shares directly held by Platinum Falcon. The filing provides specific voting and dispositive power counts for each reporting person.

Watch for future filings if either reporting person files amendments or a Form 13D that would change disclosure status.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: (1) Abu Dhabi Investment Authority is the direct owner of 1,669,576 of the shares of Common Stock represented herein. (2) The percent calculation is based on 53,984,337 shares of Common Stock outstanding, after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation based on 53,984,337 shares of Common Stock outstanding after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.


SCHEDULE 13G



Abu Dhabi Investment Authority
Signature:/s/ Saif Surour Omair Maaded AlMashghouni
Name/Title:Authorized Signatory
Date:02/18/2026
Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
Name/Title:Authorized Signatory
Date:02/18/2026
Platinum Falcon B 2018 RSC Limited
Signature:/s/ Saif Surour Omair Maaded AlMashghouni
Name/Title:Authorized Signatory
Date:02/18/2026
Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
Name/Title:Authorized Signatory
Date:02/18/2026
Exhibit Information

Exhibit 1: Joint Filing Agreement

FAQ

How many EIKN shares does Abu Dhabi Investment Authority report owning?

Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares, consisting of 1,669,576 direct shares and 1,147,138 held via Platinum Falcon, per the filing.

What percentage of Eikon Therapeutics (EIKN) does ADIA own?

The filing states ADIA's position represents 5.2% of the class, calculated using 53,984,337 shares outstanding after the offering described in the prospectus filed on February 5, 2026.

Who is Platinum Falcon B 2018 RSC Limited in relation to ADIA?

Platinum Falcon is a wholly owned subsidiary of ADIA and is reported as the direct owner of 1,147,138 shares; the filing notes ADIA may be deemed beneficial owner under applicable rules.

What voting and dispositive powers are disclosed for ADIA and Platinum Falcon?

ADIA is reported with 1,669,576 sole voting and dispositive power and 1,147,138 shared voting and dispositive power; Platinum Falcon shows 1,147,138 shared voting and dispositive power.

On what share count is the percent ownership based?

Percentages are based on 53,984,337 shares outstanding, "after giving effect to the completion of the offering" described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.
Eikon Therapeutics

NASDAQ:EIKN

View EIKN Stock Overview

EIKN Rankings

EIKN Latest News

EIKN Latest SEC Filings

EIKN Stock Data

568.46M
17.65M
Biotechnology
Healthcare
Link
United States
Millbrae